Citius Pharmaceuticals (CTXR) Price to Sales (2025 - 2026)

Citius Pharmaceuticals' (CTXR) quarterly Price to Sales came in at 11.03 in Q2 2026, down 8.71% quarter-over-quarter from 12.08 in Q1 2026.

Analysis

Citius Pharmaceuticals (CTXR) Price to Sales (2025 - 2026) Analysis & Trends

Citius Pharmaceuticals (CTXR) has reported Price to Sales for 2 consecutive years, with 11.03 the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	640.32 Bn	619.56 Bn	17.26 Bn
2	AbbVie	445.20 Bn	438.64 Bn	12.70 Bn
3	Merck	357.17 Bn	350.03 Bn	12.21 Bn
4	Novartis Ag	267.38 Bn	259.69 Bn	11.24 Bn
5	Pfizer	156.69 Bn	145.00 Bn	10.94 Bn
6	Sanofi	52.12 Bn	44.74 Bn	10.79 Bn
7	Revolution Medicines	42.92 Bn	42.92 Bn	-
8	Incyte	24.60 Bn	20.06 Bn	1.57 Bn
9	United Therapeutics	21.29 Bn	18.63 Bn	683.80 Mn
10	Citius Pharmaceuticals	15.47 Mn	15.47 Mn	1.00 Mn

Historic Data

Download Data